Sangamo BioSciences (SGMO) PT Raised to $30 at Barclays

Barclays raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $30.00 (from $20.00) while maintaining a Overweight rating.

Analyst Gena Wang ups the price target to reflect technology capabilities at the company and progress in clinical programs. The analyst says the with KITE/GILD to exclusive license use of SGMO's ZFN platform in allogeneic and autologous cell therapies is another boost to the ZFN platform and will now eye data on HemoA.

You May Also Be Interested In

• FTAI Infrastructure (FIP) PT Lowered to $12 at Compass Point
• Wolfe Research Downgrades Simon Property Group (SPG) to Peerperform
• Carnival Corporation (CCL) PT Raised to $42 at Tigress Financial Partners